DexCom, Inc.DXCMNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank18
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P18
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -5.90% |
| Q3 2025 | 6.28% |
| Q2 2025 | 2.07% |
| Q1 2025 | 4.09% |
| Q4 2024 | 3.03% |
| Q3 2024 | -0.44% |
| Q2 2024 | -3.89% |
| Q1 2024 | 3.97% |
| Q4 2023 | 3.58% |
| Q3 2023 | 10.14% |
| Q2 2023 | 0.25% |
| Q1 2023 | 2.32% |
| Q4 2022 | 5.44% |
| Q3 2022 | -9.37% |
| Q2 2022 | -10.45% |
| Q1 2022 | -42.63% |
| Q4 2021 | 83.93% |
| Q3 2021 | -0.23% |
| Q2 2021 | 18.01% |
| Q1 2021 | -8.22% |
| Q4 2020 | 35.92% |
| Q3 2020 | 9.76% |
| Q2 2020 | 9.30% |
| Q1 2020 | -7.23% |
| Q4 2019 | 18.14% |
| Q3 2019 | -3.33% |
| Q2 2019 | 16.95% |
| Q1 2019 | -78.57% |
| Q4 2018 | 449.50% |
| Q3 2018 | 6.14% |
| Q2 2018 | 5.36% |
| Q1 2018 | -8.01% |
| Q4 2017 | 12.47% |
| Q3 2017 | -4.42% |
| Q2 2017 | -5.82% |
| Q1 2017 | 10.07% |
| Q4 2016 | -0.46% |
| Q3 2016 | 20.94% |
| Q2 2016 | 12.73% |
| Q1 2016 | 12.98% |